Multidimensional Roles of Deubiquitinases in Tumor Glycolytic Reprogramming
- 1Department of Nephrology, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China
- 2Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, China
- 3School of Basic Medical Sciences, Guilin Medical University, Guilin 541199, China
Abstract
Tumor glycolytic reprogramming is an important metabolic hallmark of malignant tumors and plays a key role in sustaining tumor cell proliferation, adapting to microenvironmental changes, and promoting tumor progression. In recent years, deubiquitinating enzymes (DUBs), as important regulators of post-translational protein modification, have attracted extensive attention for their roles in tumor glycolytic reprogramming. Studies have shown that DUBs can not only directly affect glycolysis by regulating the stability and functional status of key glycolytic enzymes, glucose transporters, and upstream transcriptional regulators, but also indirectly regulate glucose metabolism through signaling pathways such as AMPK, mTOR, HIF-1, and PI3K/AKT. In addition, DUBs can participate in the interplay between tumor metabolism and the immune microenvironment by affecting lactate production in tumor cells, metabolic adaptation of immune cells, and immune checkpoint signaling. Notably, glucose metabolism-related products and changes in metabolic status can also reciprocally regulate the expression and function of DUBs through mechanisms such as lactylation, O-GlcNAcylation, and phosphorylation, suggesting that bidirectional feedback regulation may exist between the two. Drugs targeting DUBs have shown potential to interfere with glycolysis and inhibit tumor progression in some preclinical tumor models; however, their clinical translation still faces challenges, including context-dependent mechanisms of action, inhibitor selectivity, and safety. This article systematically reviews the molecular mechanisms by which DUBs regulate tumor glycolytic reprogramming, with a focus on their roles in metabolic signal transduction, interactions with the tumor immune microenvironment, and metabolic feedback regulation, and summarizes the research progress and existing issues in related targeted intervention strategies, aiming to provide new insights for mechanistic studies of tumor metabolic reprogramming and precision therapy.
Related
- Hypoxia-Associated Glycolytic–Lipogenic Reprogramming and Impaired Antigen Presentation in SPP1+ Tumor-Associated Macrophages in Ovarian Cancer
- TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers
- Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications
- From Single-Modal Signal Recognition to Multidimensional Precision Detection: Breakthroughs and Innovations of Multi-Modal Sensors in Tumor Biomarker Detection.
- Computer-Aided Drug Design for Immunosuppressive Tumor Microenvironment Reprogramming: A Critical Review
BibTeX
@article{zhao2026multidimensional,
title = {{Multidimensional Roles of Deubiquitinases in Tumor Glycolytic Reprogramming}},
author = {Jiawei Zhao and Zhicai Zhao and Shiqi Zang and Xiaotong Guo and Jingyi Zhang and Jinfeng Yang and Xingyu Mu and Bin Li and Jingjing Du and Gang Xu and Lin Qi and Juzheng Zhang and Jian Chen and Jiamin Jin and Zuyang Ye},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219856},
url = {https://www.mdpi.com/1422-0067/27/21/9856},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Multidimensional Roles of Deubiquitinases in Tumor Glycolytic Reprogramming
AU - Jiawei Zhao
AU - Zhicai Zhao
AU - Shiqi Zang
AU - Xiaotong Guo
AU - Jingyi Zhang
AU - Jinfeng Yang
AU - Xingyu Mu
AU - Bin Li
AU - Jingjing Du
AU - Gang Xu
AU - Lin Qi
AU - Juzheng Zhang
AU - Jian Chen
AU - Jiamin Jin
AU - Zuyang Ye
PY - 2026
DA - 2026/11/03
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219856
UR - https://www.mdpi.com/1422-0067/27/21/9856
AB - Tumor glycolytic reprogramming is an important metabolic hallmark of malignant tumors and plays a key role in sustaining tumor cell proliferation, adapting to microenvironmental changes, and promoting tumor progression. In recent years, deubiquitinating enzymes (DUBs), as important regulators of post-translational protein modification, have attracted extensive attention for their roles in tumor glycolytic reprogramming. Studies have shown that DUBs can not only directly affect glycolysis by regulating the stability and functional status of key glycolytic enzymes, glucose transporters, and upstream transcriptional regulators, but also indirectly regulate glucose metabolism through signaling pathways such as AMPK, mTOR, HIF-1, and PI3K/AKT. In addition, DUBs can participate in the interplay between tumor metabolism and the immune microenvironment by affecting lactate production in tumor cells, metabolic adaptation of immune cells, and immune checkpoint signaling. Notably, glucose metabolism-related products and changes in metabolic status can also reciprocally regulate the expression and function of DUBs through mechanisms such as lactylation, O-GlcNAcylation, and phosphorylation, suggesting that bidirectional feedback regulation may exist between the two. Drugs targeting DUBs have shown potential to interfere with glycolysis and inhibit tumor progression in some preclinical tumor models; however, their clinical translation still faces challenges, including context-dependent mechanisms of action, inhibitor selectivity, and safety. This article systematically reviews the molecular mechanisms by which DUBs regulate tumor glycolytic reprogramming, with a focus on their roles in metabolic signal transduction, interactions with the tumor immune microenvironment, and metabolic feedback regulation, and summarizes the research progress and existing issues in related targeted intervention strategies, aiming to provide new insights for mechanistic studies of tumor metabolic reprogramming and precision therapy.
SN - 1422-0067
ER -